Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The SPINOUT-F trial has been given the green light and is now open to recruitment.

Back pain related to spinal disorders is one of the most common conditions requiring surgery in the NHS. There is currently no agreement about the best surgical treatment for these patients.

To provide evidence for continuing surgical practice, a multicentre RCT is required. However, it is unsure if this would be feasible in the NHS, given both surgeon and patient preference for treatments. SPINOUT-F is a feasibility study funded by the NIHR RfPB to assess if a large trial is possible. The study is sponsored by the University of Oxford and is managed by SITU, and run through OCTRU. Mr Dominique Rothenfluh is the Chief Investigator and the study will run out of 5 sites in England (Oxford, Bristol, RNOH, Birmingham & Exeter).

Similar stories

Professor David Beard awarded BOA Honorary Fellowship

Professor of Musculoskeletal and Surgical Science, David Beard, has been awarded an Honorary Fellowship by the British Orthopaedic Association.

SCIENCE spreads across the world

Oxford Trauma are pleased to open their first overseas site for the SCIENCE study.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.

PRoCuRe opens to recruitment

The Partial Rotator Cuff Tear Repair Trial (PRoCuRe) is open to recruitment at Oxford University Hospitals NHS Foundation Trust after achieving OCTRU Green Light approval!

IMP-MEL Trial given Green Light to open

OCTRU have now given Green Light approval for IMP MEL to open. This is a phase 1 first-in-human dose finding/randomised phase 2 study of IMM60 and pembrolizumab in advanced melanoma and NSCLC.